BioNTech Reports First Patient Dosing in P-II Clinical Trial of BNT111 to Treat Advanced Melanoma

 BioNTech Reports First Patient Dosing in P-II Clinical Trial of BNT111 to Treat Advanced Melanoma

BioNTech Reports First Patient Dosing in P-II Clinical Trial of BNT111 to Treat Advanced Melanoma

Shots:

  • The first patient has been dosed in a P-II cancer vaccine trial evaluating the efficacy, tolerability & safety of BNT111 + Libtayo in combination or as monothx in 120 patients with anti-PD1 r/r unresectable Stage III or IV melanoma in EU. The company also plans to start P-II trial in 2 additional programs with BNT111 in 2021
  • The 1EPs of a trial is ORR & 2EP includes ORR in monothx arms, DoR, & safety. The company holds global commercial rights to BNT111
  • The P-II trial is based on previous results from a P-I Lipo-MERIT dose-escalation trial that demonstrates a favorable safety profile for BNT111 & DOR was observed in patients with melanoma who had progressed following prior checkpoint blockade

Click here to­ read full press release/ article | Ref: Globe Newswire | Image: Hindustan Times

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post